Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Pfizer stock and Moderna stock dipped Friday — giving back some of their late Thursday gains on an upswing related to their updated Covid shots.

Covid Vaccine Rally Dashed As Pfizer, Moderna Give Back Gains On Eris' Advance

Moderna said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the "Eris" and "Fornax" subvariants in humans.

Moderna's updated COVID vaccine effective against 'Eris' variant in humans

Moderna's vaccine and new shots from Pfizer and Novavax are slated to roll out within weeks, pending potential approvals from the Food and Drug Administration.

Moderna says new Covid vaccine was effective against Eris variant in early trial

Moderna Inc. said Thursday that preliminary clinical trial data show that its updated COVID-19 vaccine is effective against newer variants that are starting to circulate widely. The shot significantly boosted neutralizing antibodies against the Eris, or EG.5, variant, as well as the Fornax FL 1.5.1 variant that is starting to surge in parts of the U.S., the company said in a release.

Moderna says updated COVID vaccine effective against widely circulating Eris variant

Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variant Updated vaccine expected to be available, pending approval, in coming weeks for fall vaccination season CAMBRIDGE, MA / ACCESSWIRE / August 17, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023 vaccination season showed a significant boost in neutralizing antibodies against EG.5 and FL.1.5.1 variants. These results suggest that Moderna's updated COVID-19 vaccine may effectively target the expected circulating variants of COVID-19 during the upcoming vaccination season.

Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants

Who knew getting sick could make you richer? Today, investors in Moderna (NASDAQ: MRNA ) certainly feel that way, as MRNA stock shoots roughly 7% higher.

MRNA Stock Alert: Why Is Moderna Up 7% Today?

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next three years.

Can Moderna (MRNA) Diversify Beyond Its COVID-19 Jab Sales?

Study participants include children up to and including 36 months who attend group child care and early childhood education settings located in Worcester and Cambridge WORCESTER, Mass. , Aug. 14, 2023 /PRNewswire/ -- UMass Chan Medical School today announced it will begin enrolling participants at group child care and early childhood education settings in Worcester and Cambridge to examine the impact of cytomegalovirus (CMV) transmission.

UMass Chan Medical School announces enrollment in study to examine impact of cytomegalovirus (CMV) transmission in early education settings

Amazon

Alexandria Real Estate Equities

Caterpillar

D.R. Horton

General Electric

Iron Mountain

KLA-Tencor

Live Nation

Martin Marietta Materials

Marathon Petroleum

NVIDIA

PulteGroup

Royal Caribbean Cruises

Sherwin-Williams

Molson Coors Brewing

T. Rowe Price Group

Weyerhaeuser

With another earnings season almost complete, it might be useful for investors to look further ahead. Each earnings season, we can see 70% to 80% of the S&P 500 “beating” consensus quarterly profit estimates.

Stock screen spotlights 20 companies whose 2024 earnings estimates have risen most sharply

Novavax

Three US pharmaceutical companies, Pfizer Inc (NYSE:PFE), Moderna Therapeutics Inc (NASDAQ:MRNA), and Novavax Inc, are gearing up to release updated Covid-19 vaccines this autumn. The new jabs are designed to combat recent strains, although not specifically the newly identified Eris variant.

Pfizer, Moderna and Novavax developing jab to combat new Covid strain

AbbVie

GlaxoSmithKline

With pharmaceutical companies, it's all about the pipeline of new medications. Drugmakers, and their pharma stocks, are judged based on sales of current medications and potential sales of future prescriptions.

3 Pharma Stocks to Sell in August Before They Crash and Burn

Healthcare continues to lag in the broader market. Year to date, the Standards and Practices (S&P) 500 Health Care index is down 2% versus a 17% gain in the benchmark S&P 500 index.

3 Healthcare Stocks to Sell in August Before They Crash and Burn

Is Moderna stock a buy after unexpectedly raising its full-year sales outlook? Is MRNA stock a buy right now?

Is Moderna Stock A Buy After Unexpectedly Raising Its 2023 Sales Outlook?

While the top- and bottom-line numbers for Moderna (MRNA) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Moderna (MRNA) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Moderna, Inc. (NASDAQ:MRNA ) Q2 2023 Results Earnings Conference Call August 3, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stéphane Bancel - Chief Executive Officer Stephen Hoge - President Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - TD Cowen Gena Wang - Barclays Capital Dina Elmonshed - Jefferies Luca Issi - RBC Capital Markets Edward Tenthoff - Piper Sandler Emmanuel Papadakis - Deutsche Bank Alexandria Hammond - Bank of America Securities Evan Wang - Guggenheim Partners Simon Baker - Redburn Partners Operator Good day and thank you for standing by. Welcome to Moderna Second Quarter 2023 Conference Call.

Moderna, Inc. (MRNA) Q2 2023 Earnings Call Transcript

Moderna said it expects up to $4 billion in sales of its COVID-19 shots to the private market during 2023, depending on U.S. vaccination rates.

Moderna expects up to $4B in COVID-19 vaccine sales to private market in 2023

Moderna (MRNA) beats expectations for earnings and sales. Management raises its product revenue guidance based on potential U.S. demand for COVID vaccines during the upcoming fall season.

Moderna (MRNA) Beats on Q2 Earnings & Sales, Raises '23 View

Moderna Inc (NASDAQ:MRNA) stock is currently enjoying a modest post-earnings pop, reversing its losses after earlier dropping to a two-year low of $108.26.

Moderna Stock Reverses Losses After 2-Year Bottom

Moderna raised its outlook for the year on Thursday, predicting $6 billion to $8 billion in Covid vaccine sales. MRNA stock edged higher.

Moderna Sees 2023 Covid Vaccine Sales In Back Half Of The Year

Moderna Inc.'s stock MRNA, -3.26% rallied 5.5% in premarket trade Thursday, after the COVID vaccine market posted a narrower-than-expected second-quarter loss and revenue that was far below last year's but still topped consensus estimates. The company had a net loss of $1.38 billion, or $3.62 a share, for the quarter, after income of $2.197 billion, or $5.24 a share, in the year-earlier period.

Moderna's stock jumps 5% premarket after narrower-than-expected loss and revenue beat

The biggest names in Covid are updating their vaccines for a fall campaign, but that might not bolster Pfizer stock and Moderna stock.

Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.

Moderna Therapeutics Inc (NASDAQ:MRNA) stock points higher in premarket as it reported better than feared second quarter earnings The mNRA vaccine maker reported a net loss of US$1.4 billion on US$300 million of revenue in its second quarter, representing a US$3.62 loss per share – versus market expectations of US$3.84 per share. Chief executive Stéphane Bancel pointed to the ‘seasonal nature' of Covid-19 as Moderna's outlook forecast full year 2023 Covid-19 vaccine sales between US$6 billion and US$8 billion, depending on Covid vaccination rates in the US.

Moderna stock seen higher on better-than-feared earnings

Moderna and its rivals Pfizer and Novavax have all seen a steep drop in sales of Covid vaccines and treatments as the world moves on from the pandemic.

Moderna shares rise on better Covid vaccine outlook despite sharp drop in sales

Moderna Inc on Thursday raised its annual forecast for COVID-19 vaccine sales to up to $8 billion on hopes of a boost in the fall season as sales move to a private market in the United States from government contracts.

Moderna sees up to $8 bln in 2023 COVID vaccine sales on private market hopes

Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62 Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination rates Company submitted its investigational RSV vaccine to several regulators globally ahead of potential 2024 launch With its partner Merck, the Company began Phase 3 trial of mRNA-4157, its individualized neoantigen therapy (INT), in combination with Keytruda®, for high-risk melanoma CAMBRIDGE, MA / ACCESSWIRE / August 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today reported financial results and provided business updates for the second quarter of 2023. "Second quarter sales were on target, given the seasonal nature of Covid.

News for Moderna Stock (MRNA)